Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Heather J. Landau, MD
Healthcare Professional Oncologist - Hematologist
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, New York, United States
Heather J. Landau is a board-certified oncologist and hematologist, and works as part of a multidisciplinary team caring for patients with hematologic disorders. She received her medical degree from Upstate Medical University followed by residency in internal medicine from University of Colorado Health Sciences Center and fellowship in hematology/oncology from Memorial Sloan Kettering Cancer Center.
Dr. Landau has a special interest and expertise in treating patients with disorders that arise in white blood cells called plasma cells, including multiple myeloma and light chain (AL) amyloidosis. Her research focuses on new treatment approaches for plasma cell disorders. Along with her colleagues she is testing targeted therapies, immunomodulatory agents, and stem cell transplantation to arrive at more-effective and less-toxic regimens for these diseases.
She is co-leading a study comparing the effectiveness of an immunomodulatory agent (lenalidomide) with that of high-dose therapy and stem cell transplantation. She is also leading a trial to determine the most effective post-stem cell transplant therapy. As the principal investigator of an ongoing trial using a risk-adapted approach to stem cell transplant followed by novel agents in AL amyloidosis, she has had the opportunity to present exciting results demonstrating significant activity and low toxicity with this approach.
Representative Publications:
myBinderRelated Content
-
Q&A with Lentzsch and Dispenzieri – ASG AL Webinar 2.24.24 – 3/8https://www.youtube.com/watch?v=lzrMgtOC...
-
Leyla Shune, MDLeyla Shune is an Associate Professor at...
-
ISA 2020 | AL Amyloidosis: MRD Negativityhttps://www.youtube.com/watch?v=ocvuObOB...
-
New, More Accessible Staging System Developed to Predict Survival for Patients With Light Chain AmyloidosisA new staging system developed with a mo...
-
U.S. Department of Veterans Affairs: AL Amyloidosis and Agent OrangeAL Amyloidosis and Agent Orange Veteran...
-
Dispenzieri: AL amyloidosis treatment: focusing on venetoclax, ASCT, and IMiDs – ASG AL Webinar 2.24.24 –...https://www.youtube.com/watch?v=lzrMgtOC...
-
Keyur B. Shah, MDDr. Keyur Shah is a Chief of the Section...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
